96 related articles for article (PubMed ID: 6135865)
21. [Complement fragment C 3d in the plasma of patients with chronic polyarthritis].
Stannat S; Peter HH; Raspe HH; Deicher H
Z Rheumatol; 1986; 45(2):47-51. PubMed ID: 3487899
[TBL] [Abstract][Full Text] [Related]
22. [Circulating immune complexes and anti-IgG antibodies in rheumatoid disease. Value of C3d assay].
Duquesnoy B; Santoro F; Siame JL; Vanhille P; Raviart B; Wattre P; Lemaitre V; Hatron PY
Rev Med Interne; 1981; 2(1):11-6. PubMed ID: 6972076
[No Abstract] [Full Text] [Related]
23. Complement C3 cleavage product in synovial fluids detected by immunofixation.
Partsch G; Bauer K; Bröll H; Petera P; Dunky A; Merétey K
Z Rheumatol; 1991; 50(2):82-5. PubMed ID: 1872046
[TBL] [Abstract][Full Text] [Related]
24. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
Davis AE; Harrison RA; Lachmann PJ
J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
[TBL] [Abstract][Full Text] [Related]
25. Heterogeneity in electrophoretic mobility of C3-derived molecules expressing D but not C-epitopes following in vivo activation of the complement system.
Teisner B; Brandslund I; Hau J; Svehag SE
Acta Pathol Microbiol Immunol Scand C; 1983 Feb; 91(1):85-7. PubMed ID: 6191520
[TBL] [Abstract][Full Text] [Related]
26. Determination of complement breakdown fragments C3d and its subfragments in health and disease.
Tamotsu M; Arai K; Fujita S; Hosotsubo K; Hayashi C; Miyai K; Miyano A; Kawanaka K; Takenaka M; Shimizu A
Diagn Immunol; 1984; 2(2):116-21. PubMed ID: 6333963
[TBL] [Abstract][Full Text] [Related]
27. [Relationship between anti-glycolipid antibodies and alternative complement pathway in pediatric renal glomerular diseases].
Mimura A; Kikkawa Y
Nihon Jinzo Gakkai Shi; 1988 Aug; 30(8):943-53. PubMed ID: 3266645
[No Abstract] [Full Text] [Related]
28. Correlation in rheumatoid arthritis of concentrations of plasma C3d, serum rheumatoid factor, immune complexes and C-reactive protein with each other and with clinical features of disease activity.
Mallya RK; Vergani D; Tee DE; Bevis L; de Beer FC; Berry H; Hamilton ED; Mace BE; Pepys MB
Clin Exp Immunol; 1982 Jun; 48(3):747-53. PubMed ID: 6981476
[TBL] [Abstract][Full Text] [Related]
29. Acute complement activation during an anaphylactoid reaction to blood transfusion and the disappearance rate of C3c and C3d from the circulation.
Teisner B; Brandslund I; Grunnet N; Hansen LK; Thellesen J; Svehag SE
J Clin Lab Immunol; 1983 Oct; 12(2):63-7. PubMed ID: 6606048
[TBL] [Abstract][Full Text] [Related]
30. Detection of a neoantigen on human C3bi and C3d by monoclonal antibody.
Tamerius JD; Pangburn MK; Müller-Eberhard HJ
J Immunol; 1985 Sep; 135(3):2015-9. PubMed ID: 2410510
[TBL] [Abstract][Full Text] [Related]
31. [Serum complement levels in patients with rheumatoid arthritis and vasculitis].
Tomooka K
Fukuoka Igaku Zasshi; 1989 Oct; 80(10):456-66. PubMed ID: 2613159
[TBL] [Abstract][Full Text] [Related]
32. Isolation and analysis of complement activating aggregates from synovial fluid of patients with rheumatoid arthritis using monoclonal anti-C3d antibodies.
Bedwell AE; Elson CJ; Carter SD; Dieppe PA; Hutton CW; Czudek R
Ann Rheum Dis; 1987 Jan; 46(1):55-64. PubMed ID: 3492971
[TBL] [Abstract][Full Text] [Related]
33. Measurement of the complement C3 breakdown product C3d by rocket immunoelectrophoresis.
Bourke BE; Moss IK; Maini RN
J Immunol Methods; 1982; 48(1):97-108. PubMed ID: 6799579
[TBL] [Abstract][Full Text] [Related]
34. Assessment of complement activation during extracorporeal circulation by measurement of complement split C3d.
Knudsen F
Blood Purif; 1987; 5(2-3):162-7. PubMed ID: 3497646
[TBL] [Abstract][Full Text] [Related]
35. The quantitation of C3d by routine methods after the direct absorption of human plasma with anti-C3c.
Mlynek Y; Nilsson M
Acta Pathol Microbiol Immunol Scand C; 1985 Oct; 93(5):195-8. PubMed ID: 3936336
[TBL] [Abstract][Full Text] [Related]
36. The third complement factor (C3) and its in vivo cleavage products: interaction with lectins and precipitation with polyethylene glycol.
Teisner B; Hau J; Svehag SE; Brandslund I; Bøg-Hansen TC
J Immunol Methods; 1984 Jan; 66(1):113-8. PubMed ID: 6607289
[TBL] [Abstract][Full Text] [Related]
37. Subnormal sensitivity of neutrophils to complement split product C5a in rheumatoid arthritis: relation to complement catabolism and disease extent.
Elmgreen J; Hansen TM
Ann Rheum Dis; 1985 Aug; 44(8):514-8. PubMed ID: 4026413
[TBL] [Abstract][Full Text] [Related]
38. Different patterns of C3 and C4 activation in the varied types of juvenile arthritis.
Miller JJ; Olds LC; Silverman ED; Milgrom H; Curd JG
Pediatr Res; 1986 Dec; 20(12):1332-7. PubMed ID: 3099253
[TBL] [Abstract][Full Text] [Related]
39. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis.
Familian A; Voskuyl AE; van Mierlo GJ; Heijst HA; Twisk JW; Dijkmans BA; Hack CE
Ann Rheum Dis; 2005 Jul; 64(7):1003-8. PubMed ID: 15958758
[TBL] [Abstract][Full Text] [Related]
40. Glomerular C3c localization indicates ongoing immune deposit formation and complement activation in experimental glomerulonephritis.
Schulze M; Pruchno CJ; Burns M; Baker PJ; Johnson RJ; Couser WG
Am J Pathol; 1993 Jan; 142(1):179-87. PubMed ID: 7678717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
